Department of Pharmaceutical Sciences, School of Pharmacy, University of Maryland, Baltimore, MD 21201, United States.
Biochem Pharmacol. 2010 Dec 1;80(11):1754-61. doi: 10.1016/j.bcp.2010.08.016. Epub 2010 Sep 9.
Induction of the breast cancer resistance protein (BCRP/ABCG2) expression has been found in various tissues and cell-types after exposure to chemicals including 17β-estradiol, rosiglitazone, imatinib, as well as aryl hydrocarbon receptor (AhR) activators such as 2,3,7,8-tetrachlorodibenzodioxin, 3-methylcholanthrene (3MC), and omeprazole. However, the mechanism(s) underlying AhR-related induction of ABCG2 is largely unknown. Here, we demonstrate the AhR-dependent induction of ABCG2 expression in human colon adenocarcinoma LS174T cells. Importantly, a novel distal AhR-responsive element (AhRE5) located -2357/-2333bp upstream of the ABCG2 transcriptional start site has been identified and characterized as a functional unit pivotal to 3MC-mediated induction of ABCG2. Cell-based reporter assays revealed that deletion of AhRE5 and 4 dramatically attenuated 3MC-induced activation of ABCG2 reporter activity, while further deletion of the proximal AhRE3 and 2 only moderately changed the luciferase activities. Notably, site-directed mutation of the AhRE5 in the BCRP-3.8kb reporter construct alone resulted in approximately 80% decrease in 3MC activation of the ABCG2 promoter; additional mutation of the AhRE4 site had negligible effect on the ABCG2 promoter activity. Moreover, chromatin immunoprecipitation assays demonstrated that treatment with 3MC significantly enhanced the recruitment of AhR to the AhRE5 occupied region, and mutation of the AhRE5 site clearly dissociated AhR protein from this promoter region. Together, these data show that the novel distal AhRE5 is critical for AhR-mediated transcriptional activation of ABCG2 gene expression in LS174T cells, and it may offer new strategies for early identification of ABCG2 inducers, which would be of benefit for preventing transporter-associated drug-drug interactions.
已经发现,在暴露于包括 17β-雌二醇、罗格列酮、伊马替尼在内的各种化学物质以及芳基烃受体 (AhR) 激活剂(如 2,3,7,8-四氯二苯并二恶英、3-甲基胆蒽 (3MC) 和奥美拉唑)后,乳腺癌耐药蛋白 (BCRP/ABCG2) 的表达在各种组织和细胞类型中被诱导。然而,AhR 相关诱导 ABCG2 的机制在很大程度上尚不清楚。在这里,我们证明了 AhR 依赖性诱导人结肠腺癌 LS174T 细胞中 ABCG2 的表达。重要的是,已经鉴定并表征了位于 ABCG2 转录起始位点上游-2357/-2333bp 的新型远端 AhR 反应元件 (AhRE5),作为 3MC 介导的 ABCG2 诱导的关键功能单元。基于细胞的报告基因检测显示,AhRE5 和 4 的缺失极大地减弱了 3MC 诱导的 ABCG2 报告基因活性,而 AhRE3 和 2 的近端缺失仅适度改变了荧光素酶活性。值得注意的是,单独突变 BCRP-3.8kb 报告基因构建体中的 AhRE5 位点导致 3MC 对 ABCG2 启动子的激活降低约 80%;进一步突变 AhRE4 位点对 ABCG2 启动子活性几乎没有影响。此外,染色质免疫沉淀测定表明,用 3MC 处理显著增强了 AhR 募集到 AhRE5 占据区域的能力,而突变 AhRE5 位点明显将 AhR 蛋白从该启动子区域中分离出来。总之,这些数据表明,新型远端 AhRE5 对于 LS174T 细胞中 AhR 介导的 ABCG2 基因表达的转录激活至关重要,它可能为早期鉴定 ABCG2 诱导剂提供新策略,这将有利于预防转运体相关的药物-药物相互作用。